Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment

B oston, MA (September 20, 2022) – Glyscend Therapeutics , a clinical-stage biotechnology company, today reported additional biomarker results from their Phase 1 study of GLY-200, a proprietary orally administered, gut-restricted therapeutic for the treatment of type 2 diabetes (T2D). Glyscend also received clearance from the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application to… LEARN MORE

The release as fetched from its publisher. glyscend.com ↗